Recent News Items

Contact Us     Home

J. Scott Tarrant Joins Accium BioSciences as Vice President of Corporate Development

Accium BioSciences is pleased to announce the addition of J. Scott Tarrant as the company's Vice President of Corporate Development.  Most recently Scott served as Executive Vice President of Global Sales and Marketing for UK based Xceleron Ltd, a specialty CRO utilizing accelerator mass spectrometry (AMS) to obtain early ADME and PK data in exploratory clinical development.

In his new role at Accium, Scott will drive the company's efforts to bring AMS-based services to the broader early phase drug development market while the company continues its commitment to the highest standards of quality and value.

Scott’s addition is part of a six month growth effort at Accium BioSciences aimed at delivering expanded service capability, increased sample capacity, faster turnaround and higher quality. We recently announced the addition of a second and larger ion source to our AMS instrument which increases the measurement capacity of the instrument. We also implemented an improved sample tracking and documentation system which has already resulted in speedier QA review and release of Final Reports.

For inquiries on new studies, please contact Scott Tarrant, Vice President of Corporate Development by telephone or e-mail

Accium BioSciences is expanding its AMS service operations by implementing a new sample documentation system and a large-capacity sample injector for its AMS instrument.

• A new sample documentation, sample tracking and chain-of-custody system has been implemented at Accium. The new system provides much more efficient documentation of sample preparation and tracking and improves productivity and turnaround-time for each study. 

• Accium's AMS instrument will be upgraded in July 2009 with the addition of a new sample injector ion source. Running in conjunction with the existing 40-sample injector, the new 134-sample injector will increase throughput and measurement capacity by at least three-fold. This means more data points will be generated in a 24-hour period, helping to speed study turnaround time and overall service capacity!

Accium BioSciences, Pioneer of Particle Accelerator for Drug Development, Finds Niche Xconomy

May 20, 2007

Accium Announces Publication in RADIOCARBON

Performance Evaluation of New Accelerator Mass Spectrometer at Accium BioSciences

Ugo Zoppi, James Crye, Qi Song, Ali Arjomand

October 19, 2006

Accium BioSciences and CMIC Announce Strategic Alliance to Provide Exploratory IND and Low-Radiation PK/ADME Services to the Japanese Pharmaceutical Industry

May 23, 2006

May 23, 2006

Battelle, BattelleCRO, and Accium Biosciences Form Collaboration to Speed Product Development Cycle

January 5, 2006

Accium BioSciences Finances Microdosing Operation, Brings on Key Personnel

Accium BioSciences and Radiant Research Forge Strategic Co-Marketing Agreement

FDA Clears Path for Exploratory IND Studies

Zeroing in on Microdosing

Thompson CenterWatch Monthly; Vol.12, Issue 2 February 2005

FDA Developing Guidance on Exploratory INDs

The PINK Sheet Daily; Vol 66, No.48 November 29, 2004

Pushing Phase 0

Drug Discovery News; August 19, 2005

Winnowing Out Drug Candidates

Chemical and Engineering News: Vol. 83, No. 28, July 11, 2005

Copyright © Accium BioSciences, Inc. 2004-2010